FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099694564> ?p ?o ?g. }

• W2099694564 endingPage "500" @default.
• W2099694564 startingPage "489" @default.
• W2099694564 abstract "Background Procedures to prevent severe graft-versus-host disease (GVHD) delay immune reconstitution secondary to transplants of haploidentical haemopoietic stem cells for the treatment of leukaemia, leading to high rates of late infectious mortality. We aimed to systematically add back genetically engineered donor lymphocytes to facilitate immune reconstitution and prevent late mortality. Methods In a phase I–II, multicentre, non-randomised trial of haploidentical stem-cell transplantation, we infused donor lymphocytes expressing herpes-simplex thymidine kinase suicide gene (TK-cells) after transplantation. The primary study endpoint was immune reconstitution defined as circulating CD3+ count of 100 cells per μL or more for two consecutive observations. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00423124. Findings From Aug 13, 2002, to March 26, 2008, 50 patients (median age 51 years, range 17–66) received haploidentical stem-cell transplants for high-risk leukaemia. Immune reconstitution was not recorded before infusion of TK-cells. 28 patients received TK-cells starting 28 days after transplantation; 22 patients obtained immune reconstitution at median 75 days (range 34–127) from transplantation and 23 days (13–42) from infusion. Ten patients developed acute GVHD (grade I–IV) and one developed chronic GVHD, which were controlled by induction of the suicide gene. Overall survival at 3 years was 49% (95% CI 25–73) for 19 patients who were in remission from primary leukaemia at the time of stem-cell transplantation. After TK-cell infusion, the last death due to infection was at 166 days, this was the only infectious death at more than 100 days. No acute or chronic adverse events were related to the gene-transfer procedure. Interpretation Infusion of TK-cells might be effective in accelerating immune reconstitution, while controlling GVHD and protecting patients from late mortality in those who are candidates for haploidentical stem-cell transplantation. Funding MolMed SpA, Italian Association for Cancer Research." @default.
• W2099694564 created "2016-06-24" @default.
• W2099694564 creator A5002350437 @default.
• W2099694564 creator A5011524049 @default.
• W2099694564 creator A5013231760 @default.
• W2099694564 creator A5014819109 @default.
• W2099694564 creator A5016760892 @default.
• W2099694564 creator A5017067720 @default.
• W2099694564 creator A5017987266 @default.
• W2099694564 creator A5018098518 @default.
• W2099694564 creator A5018345688 @default.
• W2099694564 creator A5021416524 @default.
• W2099694564 creator A5021597982 @default.
• W2099694564 creator A5026665975 @default.
• W2099694564 creator A5026667594 @default.
• W2099694564 creator A5027599215 @default.
• W2099694564 creator A5031901871 @default.
• W2099694564 creator A5032192705 @default.
• W2099694564 creator A5032815689 @default.
• W2099694564 creator A5036175544 @default.
• W2099694564 creator A5041128935 @default.
• W2099694564 creator A5044577073 @default.
• W2099694564 creator A5045261121 @default.
• W2099694564 creator A5049410134 @default.
• W2099694564 creator A5055304980 @default.
• W2099694564 creator A5059915616 @default.
• W2099694564 creator A5060440062 @default.
• W2099694564 creator A5068477953 @default.
• W2099694564 creator A5070749081 @default.
• W2099694564 creator A5071343204 @default.
• W2099694564 creator A5074043746 @default.
• W2099694564 creator A5074115908 @default.
• W2099694564 creator A5074387223 @default.
• W2099694564 creator A5074636784 @default.
• W2099694564 creator A5082045927 @default.
• W2099694564 creator A5082083571 @default.
• W2099694564 creator A5082094987 @default.
• W2099694564 creator A5084322130 @default.
• W2099694564 creator A5089992014 @default.
• W2099694564 creator A5091476321 @default.
• W2099694564 date "2009-05-01" @default.
• W2099694564 modified "2023-10-16" @default.
• W2099694564 title "Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I–II study" @default.
• W2099694564 cites W1530764705 @default.
• W2099694564 cites W1532162953 @default.
• W2099694564 cites W1965613868 @default.
• W2099694564 cites W1966252771 @default.
• W2099694564 cites W1969566486 @default.
• W2099694564 cites W1979849861 @default.
• W2099694564 cites W1982408656 @default.
• W2099694564 cites W1987746867 @default.
• W2099694564 cites W1992817791 @default.
• W2099694564 cites W2009607549 @default.
• W2099694564 cites W2022957937 @default.
• W2099694564 cites W2027582676 @default.
• W2099694564 cites W2029409133 @default.
• W2099694564 cites W2045754007 @default.
• W2099694564 cites W2046689400 @default.
• W2099694564 cites W2050152294 @default.
• W2099694564 cites W2053278212 @default.
• W2099694564 cites W2055393026 @default.
• W2099694564 cites W2072095119 @default.
• W2099694564 cites W2080773931 @default.
• W2099694564 cites W2085704445 @default.
• W2099694564 cites W2102859148 @default.
• W2099694564 cites W2104294740 @default.
• W2099694564 cites W2107369582 @default.
• W2099694564 cites W2107758715 @default.
• W2099694564 cites W2112041130 @default.
• W2099694564 cites W2112593955 @default.
• W2099694564 cites W2119627739 @default.
• W2099694564 cites W2120998952 @default.
• W2099694564 cites W2125779795 @default.
• W2099694564 cites W2130040182 @default.
• W2099694564 cites W2135067231 @default.
• W2099694564 cites W2138946470 @default.
• W2099694564 cites W2141262236 @default.
• W2099694564 cites W2147068163 @default.
• W2099694564 cites W2149936872 @default.
• W2099694564 cites W2150895619 @default.
• W2099694564 cites W2171653261 @default.
• W2099694564 cites W2317548431 @default.
• W2099694564 cites W2324265531 @default.
• W2099694564 cites W64434556 @default.
• W2099694564 cites W951670699 @default.
• W2099694564 doi "https://doi.org/10.1016/s1470-2045(09)70074-9" @default.
• W2099694564 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19345145" @default.
• W2099694564 hasPublicationYear "2009" @default.
• W2099694564 type Work @default.
• W2099694564 sameAs 2099694564 @default.
• W2099694564 citedByCount "434" @default.
• W2099694564 countsByYear W20996945642012 @default.
• W2099694564 countsByYear W20996945642013 @default.
• W2099694564 countsByYear W20996945642014 @default.
• W2099694564 countsByYear W20996945642015 @default.
• W2099694564 countsByYear W20996945642016 @default.
• W2099694564 countsByYear W20996945642017 @default.
• W2099694564 countsByYear W20996945642018 @default.

• next